Mesoblast Reports Positive Type 2 Diabetes Trial Results
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Story so far
Earlier from Mesoblast
- MSB & NIH Agree 120 Patient Trial In End-Stage Heart Failure
- MSB Accelerates Plans for Commercial Manufacturing Operation
- Mesoblast Receives $5.05m for Stem Cell Pipeline Development
- Circulation Publishes Improved Outcomes with Mesoblast Cells
- Key US Patent Granted For Treatment Of Rheumatoid Arthritis
Later from Mesoblast
- Half-Year Results & Strategic Update on Product Development
- Key mpc patents granted in united states and china
- Mesoblast Corporate Overview - CEO Message to AGM
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast